Hyderabad-based Sai Parenterals has announced the successful completion of a Rs 50 crore equity investment round by a group of marquee investors. The capital will support the company’s growth plans for establishing its international footprint as it pursues its vision to become a global pharmaceutical company.
Samarsh Capital, Vyom Partners, and funds associated with Blue Lotus Capital led the fundraising round.
Anil Karusala, Managing Director of Sai Parenterals, remarked, "We are working diligently to build a world-class pharmaceutical company that adheres to the highest global standards and practices. This equity infusion will allow us to acquire high-potential international assets and intellectual property in regulated markets, expand our product portfolio and geographical presence, and enhance our manufacturing capabilities. We are honoured by the confidence of such professional investors in our company’s strategy and future.
Sandeep Shenoy, Managing Partner of Samarsh Capital, commented, "Our investment in Sai Parenterals reflects our confidence in its solid fundamentals, scalable model, and potential to achieve strong growth in the global pharmaceutical sector. Under the visionary leadership of Anil, we expect Sai Parenterals to emerge as a leader in its segment."
With two strategic business verticals—Branded Export Formulations and Contract Development & Manufacturing Organization (CDMO) Services—Sai Parenterals focuses on delivering value-added drug formulations.
The company has built a diverse portfolio across dosage forms, including injectables, oral solids and liquids, and topical preparations. The company operates five facilities in India, of which some are approved by TGA Australia, GCC, SAPRA and WHO GMP, supporting a growing presence in both domestic and key international markets.
